Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Nov 7;18(41):5848-61.
doi: 10.3748/wjg.v18.i41.5848.

Changes of the cytokine profile in inflammatory bowel diseases

Affiliations
Review

Changes of the cytokine profile in inflammatory bowel diseases

Györgyi Műzes et al. World J Gastroenterol. .

Abstract

Cytokines are indispensable signals of the mucosa-associated immune system for maintaining normal gut homeostasis. An imbalance of their profile in favour of inflammation initiation may lead to disease states, such as that is observed in inflammatory bowel diseases (IBD). Although Crohn's disease (CD) is often described as a prototype of T-helper 1-type diseases, and ulcerative colitis (UC) is traditionally viewed as a T-helper 2-mediated condition, the classic paradigm, which categorises cytokines into pro- and anti-inflammatory groups, has recently been changed. The inflammation regulatory pathways may not be mutually exclusive as individual cytokines can have diverse and even opposing functions in various clinical and immunological settings. None the less there are many common immunological responses in IBD that are mediated by cytokines. Although they regulate and influence the development, course and recurrence of the inflammatory process, the concrete pathogenic role of these small signaling molecules is sometimes not unambiguous in the subtypes of the disease. Our aim is to review the current information about pro- and anti-inflammatory effects of traditionally studied and recently discovered cytokines in the pathogenesis of UC and CD. The better understanding of their production and functional activity may lead to the development of new therapeutic modalities.

Keywords: Crohn’s disease; Interleukin-25; Interleukin-33; Interleukin-35; Interleukin-4; Interleukin-8; Tumor necrosis factor ligand superfamily member 14; Tumor necrosis factor-like factor; Ulcerative colitis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The disease-related pathogenic role of cytokines with pro-inflammatory, anti-inflammatory and pro-fibrogenic effects in ulcerative colitis and Crohn’s disease. LIGHT: Lymphotoxins, exhibits inducible expression, and competes with herpes sipmlex virus glycoprotein D for herpesvirus entry mediator, a receptor expressed by T lymphocytes; IL: Interleukin; TNF: Tumor necrosis factor; TL1A: TNF-like factor; TGF-β: Transforming growth factor-β.

References

    1. Casini-Raggi V, Kam L, Chong YJ, Fiocchi C, Pizarro TT, Cominelli F. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J Immunol. 1995;154:2434–2440. - PubMed
    1. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427–434. - PubMed
    1. Fuss IJ, Neurath M, Boirivant M, Klein JS, de la Motte C, Strong SA, Fiocchi C, Strober W. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn’s disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol. 1996;157:1261–1270. - PubMed
    1. Bamias G, Nyce MR, De La Rue SA, Cominelli F. New concepts in the pathophysiology of inflammatory bowel disease. Ann Intern Med. 2005;143:895–904. - PubMed
    1. Dinarello CA. Interleukin-1beta and the autoinflammatory diseases. N Engl J Med. 2009;360:2467–2470. - PubMed